CD47 and non-Hodgkin lymphoma: NSG mice engrafted with NHL tumors demonstrated responsiveness to combined anti-CD47 antibodies and rituximab mediated by ADCP (Chao et al, 2010), which was then tested in patients with refractory NHL (failure to respond to conventional chemotherapy) resulting in a 36% complete response, suggesting the addition of rituximab as a promising second-line strategy (Advani et al, 2018).